KRINTAFEL has been developed since 2008 by MMV and GSK to treat malaria. A 2017 report from the Canadian Agency for Drugs and Technologies in Health summarized indirect comparisons of KRINTAFEL to other antimalarial drugs and found it exerted beneficial effects on malaria parasites in red blood cells. The RBM Partnership to end Malaria and the Bill & Melinda Gates Foundation support the development of medicines like KRINTAFEL through the Medicines for Malaria Venture.
KRINTAFEL has been developed since 2008 by MMV and GSK to treat malaria. A 2017 report from the Canadian Agency for Drugs and Technologies in Health summarized indirect comparisons of KRINTAFEL to other antimalarial drugs and found it exerted beneficial effects on malaria parasites in red blood cells. The RBM Partnership to end Malaria and the Bill & Melinda Gates Foundation support the development of medicines like KRINTAFEL through the Medicines for Malaria Venture.
KRINTAFEL has been developed since 2008 by MMV and GSK to treat malaria. A 2017 report from the Canadian Agency for Drugs and Technologies in Health summarized indirect comparisons of KRINTAFEL to other antimalarial drugs and found it exerted beneficial effects on malaria parasites in red blood cells. The RBM Partnership to end Malaria and the Bill & Melinda Gates Foundation support the development of medicines like KRINTAFEL through the Medicines for Malaria Venture.
Since 2008, KRINTAFEL has been developed by MMV and GSK.
(SUMMARY OF INDIRECT COMPARISONS, 2017)
SUMMARY OF INDIRECT COMPARISONS. (2017). [online]
www.ncbi.nlm.nih.gov. Canadian Agency for Drugs and Technologies in Health. Available at: https://www.ncbi.nlm.nih.gov/books/NBK476093/ [Accessed 9 Dec. 2022].
Genève, July 23, 2018-The RBM Partnership to end Malaria.
The Bill & Melinda Gates Foundation and the Medicines for Malaria Venture. antimalarial
A Prospective Cohort Study in Patients With Type 2 Diabetes Mellitus For Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics